461418-05-3

Upstream product

• 84348-37-8 N-tert-butoxycarbonyl-4-oxo-L-proline 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 461418-07-5 1-tert-butyl-2-methyl (2S,4EZ)-4-(methoxyimino)pyrrolidine-1,2-dicarboxylate 
• 364077-88-3 (4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-L-proline 
• 863976-38-9 1-(2’-methyl-1,1’-biphenyl-4-yl)carbonyl-4-oxo-L-proline 
• 593-56-6 N-methoxylamine hydrochloride 
• 461418-01-9 (4Z/E,2S)-methyl-1[(2’-methyl-1,1‘-biphenyl-4-yl)-carbonyl]-4-methoxyimino pyrrolidine-2-carboxylate 
• 5748-43-6 4-(2-methylphenyl)benzoic acid 
• 16419-60-6 2-Methylphenylboronic acid 

Downstream Products

• 461418-01-9 (4Z/E,2S)-methyl-1[(2’-methyl-1,1‘-biphenyl-4-yl)-carbonyl]-4-methoxyimino pyrrolidine-2-carboxylate 

Relevant academic research and scientific papers

Differential effects of oxytocin receptor antagonists, atosiban and nolasiban, on oxytocin receptor-mediated signaling in human amnion and myometrium

One of the most established roles of oxytocin (OT) is in inducing uterine contractions and labor. Apart from inducing contractions, our recent studies showed that OT can also activate proinflammatory pathways in both human myometrial and amnion cells, whi

OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE

The disclosure provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives of formula (I), among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compos

BIOMARKERS FOR OXYTOCIN RECEPTOR ANTAGONIST THERAPY

The disclosure provides compositions and methods for determining the propensity of a subject (e.g., a female human subject) undergoing embryo transfer therapy to benefit from administration of an oxytocin receptor antagonist, as well as for treating such

OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE

The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compositions and metho

CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY

Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity,

PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methy19243-yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or

PYRROLIDINE DERIVATIVES AS OXYTOCIN / VASOPRESSIN V1a RECEPTORS ANTAGONISTS

The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1- [(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or v

ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES

The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulat

ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES

The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one- O-methyloxime, and/or an active metabolite thereof, and the use of said formula

METHOD FOR PREPARING PYRROLIDINE OXIMES

The present invention is related to a new synthesis for preparing pyrrolidine oximes of general formula (I). The compounds of formula (I) are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea.